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A B S T R A C T
A constant rate infusion (CRI) of medetomidine is used to balance equine inhalation anesthesia, but its
cardiovascular side effects are a concern. This experimental crossover study aimed to evaluate the effects
of vatinoxan (a peripheral α2-adrenoceptor antagonist) on cardiorespiratory and gastrointestinal
function in anesthetized healthy horses. Six horses received medetomidine hydrochloride 7 mg/kg IV
alone (MED) or with vatinoxan hydrochloride 140 mg/kg IV (MED + V). Anesthesia was induced with
midazolam and ketamine and maintained with isoﬂurane and medetomidine CRI for 60 min. Heart rate,
carotid and pulmonary arterial pressures, central venous pressure, cardiac output and arterial and mixed
venous blood gases were measured. Selected cardiopulmonary parameters were calculated. Plasma drug
concentrations were determined. Fecal output was measured over 24 h. For statistical comparisons,
repeated measures analysis of covariance and paired t-tests were applied.
Heart rate decreased slightly from baseline in the MED group. Arterial blood pressures decreased with
both treatments, but signiﬁcantly more dobutamine was needed to maintain normotension with MED + V
(P = 0.018). Cardiac index (CI) and oxygen delivery index (DO2I) decreased signiﬁcantly more with MED,
with the largest difference observed at 20 min: CI was 39  2 and 73  18 (P = 0.009) and DO2I 7.4 1.2 and
15.3  4.8 (P = 0.014) mL/min/kg with MED and MED + V, respectively. Fecal output or plasma
concentrations of dexmedetomidine did not differ between the treatments. In conclusion, premedication
with vatinoxan induced hypotension, thus its use in anesthetized horses warrants further studies. Even
though heart rate and arterial blood pressures remained clinically acceptable with MED, cardiac
performance and oxygen delivery were lower than with MED + V.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Medetomidine and its active enantiomer dexmedetomidine are
potent α2-adrenoceptor agonists (α2-agonists) with a short half-
life in horses (Bettschart-Wolfensberger et al.,1999; Ranheim et al.,
2015). Thus, they are interesting for use as constant rate infusion
(CRI) in equine anesthesia, albeit they currently only have Market
Authorisation for dogs and cats. A medetomidine CRI reduces the
minimal alveolar concentration of inhalation agents (Bettschart-
Wolfensberger et al., 2001; Ringer et al., 2007) and improves* Corresponding author.
E-mail address: heidi.tapio@helsinki.ﬁ (H.A. Tapio).
http://dx.doi.org/10.1016/j.tvjl.2019.105345
1090-0233/© 2019 The Authors. Published by Elsevier Ltd. This is an open access articquality of recovery from general anesthesia in horses (Ringer et al.,
2007; Marcilla et al., 2012). The typical, α2-agonist-induced
cardiovascular side effects, such as increased systemic vascular
resistance (SVR), bradycardia and decreased cardiac index (CI;
Flacke et al., 1990; Yamashita et al., 2000), are a concern for its use
(Risberg et al., 2016). Furthermore, in conscious horses, medeto-
midine reduces gastrointestinal motility (Rezende et al., 2015),
which may already be decreased by general anesthesia, predis-
posing the animals to post-anesthetic colic.
Vatinoxan (previously MK-467 or L-659,066) mainly blocks
α2-adrenoceptors located outside of the central nervous system
(Clineschmidt et al., 1988). In standing horses, vatinoxan
alleviated detomidine- and romiﬁdine-induced vasoconstric-
tion, the related bradycardia, and gastrointestinal hypomotilityle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Starting rate of dobutamine infusion in relation to the initial mean arterial pressure
value obtained from the arterial catheter placed in the right common carotid artery.
Mean arterial pressure (mmHg) Rate of dobutamine infusion (mg/kg/min)
60–69 0.5
50–59 1
40–49 2
<40 4
2 H.A. Tapio et al. / The Veterinary Journal 251 (2019) 105345without a signiﬁcant effect on sedation (Vainionpää et al., 2013;
de Vries et al., 2016). Intravenous (IV) dosing of vatinoxan in
combination with detomidine for premedication before iso-
ﬂurane anesthesia, however, induced severe hypotension in
horses (Pakkanen et al., 2015). In another study, IV vatinoxan
reversed the α2-agonist-induced vasoconstriction and improved
CI during general anesthesia (maintained with isoﬂurane and
xylazine or dexmedetomidine CRI) in horses, but also resulted in
hypotension and reduced tissue perfusion (Wittenberg-Voges
et al., 2018). Both studies concluded that the optimal dose of
vatinoxan for premedication for general anesthesia needs to be
determined in horses (Pakkanen et al., 2015; Wittenberg-Voges
et al., 2018).
This study aimed ﬁrstly to evaluate the effects of vatinoxan on
cardiorespiratory function during general anesthesia maintained
with isoﬂurane and medetomidine CRI; secondly, the effects of
vatinoxan on post-anesthetic gastrointestinal function in horses
was investigated. Because vatinoxan has been shown to alter the
pharmacokinetics of some drugs, including α2-agonists in dogs
(Honkavaara et al., 2012) and horses (Vainionpää et al., 2013;
Pakkanen et al., 2015; de Vries et al., 2016), plasma concentrations
of medetomidine enantiomers, vatinoxan and induction drugs
were also analysed.
Materials and methods
Horses
The study was approved by the National Animal Experiment Board of Finland
(License number ESAVI/4789/04.10.07/2014; Approval date 19 June 2014).
Six horses (four Standardbreds, two Warmbloods; three mares and three
geldings) with a median age of 10 years (range 5–19 years) and a median
bodyweight (bwt) of 508 kg (range 451–614 kg) were studied. The horses were
considered healthy on the basis of results of physical examination and routine
hematology tests. At least 2 months before the start of this study, the right common
carotid arteries of the horses were relocated subcutaneously (Tapio et al., 2017).
Exclusion criteria included signs of systemic illness and abnormal ﬁndings in
cardiovascular status. The sample size was chosen based on results from previous
comparable studies (Vainionpää et al., 2013; Tapio et al., 2018) indicating that a
sample size of six horses would enable detection of clinically relevant differences in
cardiorespiratory parameters.
To determine the baseline values, the mean daily fecal output for each horse
was measured by collecting and weighing feces over a 3-day period. The median
of three measurements, obtained on separate days before the anesthesia for
another study (Tapio et al., 2018), was used as the baseline value for each horse for
heart rate (HR), rectal temperature, cardiac output ( _Qt), systolic, mean and
diastolic (SAP, MAP and DAP, respectively) arterial blood pressure, systolic, mean
and diastolic pulmonary arterial blood pressure (SPAP, MPAP and DPAP,
respectively), mean central venous pressure and arterial and venous blood gas
analysis.
The horses had unlimited access to water and were fed hay. Feed, but not water,
was withheld for 12 h before anesthesia and 6 h after recovery.
Study design
Each horse received two treatments in a randomized order separated by a
minimum of 14 days. Simple randomization was performed by assigning the
treatment order to each horse using a masked method, starting alternately with
each treatment.
Instrumentation
Catheter sites were subcutaneously inﬁltrated with a small amount of
mepivacaine (Scandicain 2%, AstraZeneca). Intravenous jugular catheters (Intraﬂon,
Laboratoires Pharmaceutiques Vygon), central venous catheters (Cavaﬁx Certo, B.
Braun) and pulmonary arterial catheters (Arrow-Berman angiographic catheter,
Arrow International) were aseptically placed before each anesthesia and before
administration of premedication. The correct locations of the central venous
catheter and pulmonary arterial catheter were veriﬁed by characteristic pressure
wave forms on the monitor screen (S/5 compact Critical Care Monitor, Datex
Ohmeda). Transducer accuracy was veriﬁed against a mercury manometer in the
measurement range prior to use. An arterial catheter (BD arterial cannula, Becton-
Dickinson Critical Care Systems) was placed into the right common carotid artery
after the induction of anesthesia.Anesthesia
Horses received an IV bolus of medetomidine hydrochloride (Dorbene, Vetcare)
7 mg/kg alone (MED) or with (MED + V) vatinoxan hydrochloride 140 mg/kg.
Medications were diluted in saline (Natriumklorid 0.9%, B. Braun) to achieve a
total volume of 20 mL, and the bolus was given over 15 s. Anesthesia was induced
10 min later, at T0, with midazolam (Midazolam Accord, Accord Healthcare Ltd.)
0.06 mg/kg and ketamine (Ketador, Richter Pharma AG) 2.2 mg/kg given as an IV
bolus over 15 s. After endotracheal intubation, the horse was positioned in dorsal
recumbency on a padded surgical table. Anesthesia was maintained with isoﬂurane
(IsoFlo, Zoetis) in 100% oxygen, initiated immediately after connecting the horse to
the breathing circuit (Tafonius, Hallowell EMC), and medetomidine CRI at 3.5 mg/
kg/h, initiated 10 min after induction (T10). The expiratory isoﬂurane was set at
1.2 vol% and adjusted in the presence of spontaneous nystagmus or absence of
palpebral reﬂex by 0.1%. All horses were mechanically ventilated with an initial rate
of 8 breaths/min and a tidal volume of 12 mL/kg. Ventilation was adjusted to
maintain target expiratory CO2 (PECO2) at 35–55 mmHg. Dobutamine infusion
(Dobuject, Primex Pharmaceuticals) was started at T10 at a rate based on the ﬁrst
MAP reading (Table 1). The dose rate was then doubled every 5 min until MAP was
in the target range of 70–80 mmHg by a blinded investigator (MRR). When MAP was
>90 mmHg, the dobutamine infusion was stopped. Ringer’s solution (Fresenius Kabi
AB) was administered at a rate of 3 mL/kg/h. The medetomidine CRI was continued
for 60 min (until T70). The horse was then transferred to the recovery box and
extubated once swallowing. The recovery was unassisted.
Data collection
Sedation was scored prior to premedication (baseline) and 1 min prior to
induction of anesthesia (T-1) by a blinded investigator (MRR) with a range of
possible scores from 0 (no sedation) to 10 (heavy standing sedation) (Rohrbach
et al., 2009). Time from administration of induction drugs to lateral recumbency
was recorded, and quality of induction was scored (Rossetti et al., 2008) from 0
(excellent) to 5 (poor). During anesthesia the following parameters were recorded
every 5 min, from T10 through to T70: HR, SAP, MAP, DAP, Systolic Pulmonary
Arterial Pressure (SPAP), Mean Pulmonary Arterial Pressure (MPAP), Diastolic
Pulmonary Arterial Pressure (DPAP), inspired oxygen fraction and PECO2. Central
venous pressure, _Qt and arterial and mixed venous blood gas analysis were
recorded at T20, T40 and T70. Cardiac output was determined by lithium dilution
method (LiDCO Plus, LiDCO) as previously described (Hallowell and Corley, 2005).
The initially entered standard values of 6.2 mmol/L of hemoglobin and 140 mmol/L
of sodium were replaced by the measured values for the calculations. Arterial and
mixed venous blood was anerobically collected, placed in iced water and analysed
(ABL800 Flex, Radiometer Medical) within 10 min of sample collection. The values
were temperature-corrected on the basis of concurrently recorded rectal
temperature.
The following variables were calculated afterwards: cardiac index (CI), stroke
volume index (SVI), systemic resistance index (SVRI), pulmonary vascular
resistance index (PVRI), left ventricular workload (LVW), arterial (CaO2) and mixed
venous (C⊽O2) oxygen contents, venous admixture, arterial (SaO2) and mixed
venous (S⊽O2) blood oxygen saturation, oxygen delivery index (DO2I), oxygen
consumption (VO2I), oxygen extraction (O2ER) and alveolar dead space ventilation
(VDalv:VT; Boyd et al., 1991; Clerbaux et al., 1993; Hardman and Aitkenhead, 2003;
Haskins et al., 2005; see Supplement, Formulae for the calculated parameters).
The total amount of dobutamine administered was recorded. Recovery was
observed and the times from termination of anesthesia to extubation, sternal
recumbency and standing were recorded. Horses were observed at least every other
hour and the fecal output was determined for 24 h after recovery. In addition,
bronchoalveolar lavage samples related to another study were collected without
medication from the same horses for 156 h after anesthesia; these results will be
published elsewhere.
Arterial blood samples (10 mL) for analysis of plasma concentrations
dexmedetomidine, levomedetomidine, vatinoxan, midazolam and ketamine were
collected into EDTA-containing tubes at T-1, T20, T40 and T70 (see Supplement).
Statistical analysis
Statistical analyses were performed with commercial software (SAS, SAS
Institute Inc., and SPSS, IBM).
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variables, except for those measured only during anesthesia (venous admixture and
VDalv:VT), SaO2 and S⊽O2. The differences between treatments were assessed with
repeated measures analysis of covariance. The model consisted of a baseline
covariate, the main effects of treatment, period, sequence and time point of
measurement and two-way interactions of period*time point, sequence*time point
and treatment*time point as ﬁxed effects and the main effect of horse and two-way
interaction terms of period*horse and time point*horse as a random effect. For
venous admixture and VDalv:VT, the same model as described above, excluding the
baseline covariate and using the actual values instead of change as the response,
was used. The normality assumptions were checked using Kolmogorov–Smirnov
tests. For SaO2, S⊽O2, SPAP, MPAP and DPAP, the normality could not be veriﬁed, thus
non-parametric Wilcoxon signed-rank sum testing by time point was performed.
Estimates of treatment effect and within treatment changes were calculated from
the ﬁtted models over time and by time point using model contrasts.
For the amount of dobutamine, plasma drug concentrations, total fecal output,
induction and recovery times, the normality assumptions were conﬁrmed with
Shapiro–Wilk test, and paired t-test was then applied to investigate differences
between the treatments. For the sedation and induction scores, Wilcoxon signed-
rank sum test was applied to investigate differences between the treatments.
Statistical signiﬁcance was set at P < 0.05.
Results
There were no adverse events during the experiment, and none
of the horses were excluded from the study.
All horses were sedated after medetomidine (Table 2). Induc-
tion was signiﬁcantly faster with MED + V than with MED alone
(Table 2).
Compared to baseline, HR was signiﬁcantly higher at T10 with
MED + V and signiﬁcantly lower at T20, 40 and 60 with MED. These
changes from baseline were signiﬁcantly different between the
two treatments only at T10 (Table 3). Overall, arterial blood
pressures signiﬁcantly decreased from baseline within both
treatments, but signiﬁcantly more dobutamine was administered
with MED + V than with MED to maintain MAP in the target range
(Table 2). The range of the dobutamine CRI rate was 0–1 mg/kg/min
with MED and 0–4 mg/kg/min with MED + V. Carotid arterial
pressures decreased signiﬁcantly more from baseline with MED + V
than with MED at their ﬁrst measurement at T10 (Table 3).
Thereafter (i.e. after initiation of dobutamine CRI), SAP tended to be
higher and DAP lower with MED + V than with MED but the change
from baseline differed signiﬁcantly between the treatments only at
T30, 40 and 70 for SAP and T40 for DAP. Pulmonary arterial
pressures differed between treatments only at T30 and T40; SPAP
decreased signiﬁcantly more from baseline with MED than withTable 2
Median (minimum, maximum) sedation and induction scores and mean (
standard deviation) induction and recovery times, amount of dobutamine
administered and total fecal output of six adult horses. The horses were
administered as premedication medetomidine 7 mg/kg alone (MED) or with
vatinoxan 140 mg/kg (MED + V) and sedation was scored 1 min before induction (T-
1). Anesthesia was induced with midazolam 0.06 mg/kg and ketamine 2.2 mg/kg
10 min after premedication and maintained with isoﬂurane and medetomidine CRI
3.5 mg/kg/h for 1 h. Dobutamine was administered to maintain normotension
according to a previously deﬁned intervention plan. Times for recovery were
recorded from the cessation of CRI. Total fecal output was recorded over 24 h after
anesthesia.
Baseline MED MED + V P
Sedation score at T-1 1  0.3 6.5 (6, 7)a 6.5 (5, 7)a 0.414
Induction score – 1 (1, 1) 2  (1, 3) 0.063
Induction time (s) – 83  11 63  10 0.008
Time of extubation (min) – 20  7 25  4 0.305
Time of sternal (min) – 34  8 34  7 0.973
Time of standing (min) – 39  5 39  15 0.876
Total amount of dobutamine
(mg/kg)
– 27  16 67  25 0.018
Total fecal output (kg) 23  4 13  4a 11  3a 0.423
Number of piles of feces 14  2 9  2a 10  2a 0.542
a Signiﬁcant difference (P < 0.05) within treatment with respect to baseline.
P-values refer to statistical difference between the treatments.MED + V (Table 3). There were no signiﬁcant changes in PVRI
overall (Table 3). Central venous pressure signiﬁcantly decreased
from baseline with both treatments. Furthermore, signiﬁcant
decreases from baseline were observed in CI, SVI and DO2I and
signiﬁcant increases in SVRI and O2ER with MED, while with MED
+ V only CI decreased from baseline at T70 (Table 4). Of these
parameters, the changes from baseline differed between the
treatments only with CI, DO2I and O2ER. Left ventricular workload
decreased signiﬁcantly more from baseline with MED than with
MED + V (Table 4). Conversely, no changes in Hb, P⊽O2, C⊽O2 and
CaO2were observed with MED, whereas they transiently increased
from baseline with MED + V (Table 4). No differences were detected
between the treatments in the increase of PaO2 or the decrease of
VO2I from baseline during anesthesia or in VDalv:VT or venous
admixture (Table 4). The arterial blood O2 saturation was 98% in
all horses and there was no signiﬁcant difference between the
treatments (data not shown); S⊽O2 was signiﬁcantly higher with
MED + V than with MED (Table 4).
All recoveries were uneventful, and there were no differences in
recovery times between the treatments (Table 1). Fecal output was
markedly decreased after anesthesia without any difference
between the treatments (Table 1). None of the horses developed
any clinical signs of abdominal discomfort.
Of the measured plasma drug concentrations, only ketamine
concentrations differed signiﬁcantly between treatments; they
were lower in the MED + V group (see Supplement, Plasma drug
concentration analysis).
Discussion
In this study, adding vatinoxan to the premedication regimen
for isoﬂurane anesthesia balanced with medetomidine CRI
resulted in signiﬁcant hypotension during anesthesia in healthy
horses. Hypotension responded to dobutamine treatment and,
consequently, tissue oxygen delivery was improved compared to
MED alone. Isoﬂurane has hypotensive effects in horses (Grosen-
baugh and Muir, 1998). Furthermore, dorsal recumbency can
exacerbate hypotension by decreasing venous return, as suggested
by our ﬁnding of decreased CVP. Medetomidine counteracts these
effects by causing vasoconstriction, thus maintaining higher MAP
and SVR during isoﬂurane anesthesia (Ringer et al., 2007; Risberg
et al., 2016). Vatinoxan apparently antagonized the vasoconstric-
tion, which consequently led to hypotension, as suggested in
earlier reports (Pakkanen et al., 2015; Wittenberg-Voges et al.,
2018) and also by our ﬁnding that SVRI tended to be higher with
MED. Despite the dose of vatinoxan used in the present study being
smaller (140 mg/kg) than the ones used in earlier equine reports
(200–250 mg/kg; Pakkanen et al., 2015; Wittenberg-Voges et al.,
2018) hypotension was still observed. Conversely, in standing
horses vatinoxan alone did not induce changes in arterial blood
pressure (de Vries et al., 2016). The effect of vatinoxan on the
cardiovascular changes induced by dexmedetomidine was dose-
dependent in dogs (Honkavaara et al., 2011). Thus, further dose-
response studies of vatinoxan are warranted to limit its hypoten-
sive effect in anesthetized horses, especially when vatinoxan is
combined with medetomidine that suppresses cardiovascular
function in horses to a lesser extent than other α2-agonists
(Bettschart-Wolfensberger et al., 1999; Yamashita et al., 2000).
Signiﬁcantly more dobutamine was needed to maintain
normotension with MED + V than with MED. As a positive inotropic
agent, dobutamine can confound the interpretation of the
cardiovascular observations. Indeed, we observed improved
cardiac performance with MED + V relative to MED, but it is not
possible to differentiate the effects of vatinoxan and dobutamine.
The study design is limited by lack of cardiorespiratory
measurements during the anesthesia prior to administration of
Table 3
Mean ( standard deviation) heart rate, carotid and pulmonary arterial pressures of six horses before (baseline) and during general anesthesia maintained with isoﬂurane and
medetomidine CRI 3.5 mg/kg/h from 10 min after induction (T10) to the end of general anesthesia at 70 min (T70). The horses were administered as premedication
medetomidine 7 mg/kg alone (MED) or with vatinoxan 140 mg/kg (MED + V) 10 min before induction with midazolam 0.06 mg/kg and ketamine 2.2 mg/kg. Baseline values
were obtained prior to general anesthesia as a mean of three separate measurements in the same standing unmedicated horses.
Variable Baseline Treatment T10 T20 T30 T40 T50 T60 T70
HR
(beats/min)
37  4.5 MED 34  3.6 29  3.9b 31  4.8 31  3.7b 32  5.0 30  4.5b 31  5.3
MED + V 42  13.4a,b 33  4.6 35  7.9 34  4.4 35  6.3 33  5.0 36  5.4
SAP (mmHg) 152  12.2 MED 102  21.9b 102  11.7b 95  15.1b 98  6.8b 95  11.2b 106  12.9b 92  8.0b
MED + V 76  15.7a,b 112  11.7b 123  21.0a,b 118  27.4a,b 111  13.7b 120  20.7b 111  20.5a,b
MAP (mmHg) 123  10.5 MED 77  21.0b 80  8.0b 68  15.7b 74  10.1b 71  6.4b 82  5.2b 75  6.1b
MED + V 52  12.1a,b 83  21.9b 76  9.9b 80  14.1b 71  11.1b 79  3.9b 73  4.6b
DAP (mmHg) 101  9.6 MED 68  23.9b 72  9.8b 67  10.0b 74  6.9b 60  6.6b 73  5.7b 64  4.9b
MED + V 41  12.4a,b 66  23.0b 60  8.1b 59  8.9a,b 58  13.7b 62  4.7b 62  6.4b
SPAP (mmHg) 43  5.9 MED 0  5.6 6  4.7 6  5.1 8  3.4 7  6.1 9  5.3 8  5.3
MED + V 11  12.6 25  25.2 20  11.1a 18  10.5a 17  5.6 17  10.6 14  9.6
MPAP (mmHg) 24  5.2 MED 4  6.1 0  3.1 1  1.6 1  3.7 1  3.9 1  4.7 0  4.8
MED + V 3  12.9 11  26.0 3  3.3 5  5.5 1  4.9 2  4.2 2  4.7
DPAP (mmHg) 7  5.0 MED 9  6.6 8  5.7 9  3.1 8  5.1 8  6.3 7  6.4 8  5.9
MED + V 6  16.2 3  27.4 6  4.6 3  7.6 8  4.1 7  5.1 7  4.3
HR, heart rate; SAP, systolic arterial pressure; MAP, mean arterial pressure; DAP, diastolic arterial pressure; SPAP, systolic pulmonary arterial pressure; MPAP, mean pulmonary
arterial pressure; DPAP, diastolic pulmonary arterial pressure.
a Signiﬁcant differences (P < 0.05) between treatments (compared to baseline).
b Within treatment differences (P < 0.05) compared to baseline at a given time point.
Table 4
Mean ( standard deviation) cardiorespiratory variables and blood gas analysis results of six horses before (baseline) and during general anesthesia maintained with
isoﬂurane and medetomidine CRI 3.5 mg/kg/h from 10 min after induction (T10) to the end of general anesthesia at 70 min (T70). The horses were administered as
premedication medetomidine 7 mg/kg alone (MED) or with vatinoxan 140 mg/kg (MED + V) 10 min before induction with midazolam 0.06 mg/kg and ketamine 2.2 mg/kg.
Baseline values were obtained prior to general anesthesia as a mean of three separate measurements in the same standing unmedicated horses.
Variable Baseline Treatment T20 T40 T70
Cardiac index
(mL/min/kg)
79  19 MED 39  2b 47  10b 46  7b
MED + V 73  18a 69  15a 62  26b
Hemoglobin
(g/L)
136  12 MED 128  12 133  15 129  13
MED + V 143  14 153  13b 147  19
Mean central venous pressure
(mmHg)
10  3.4 MED 9  2.7b 8  3.5b 8  4.7b
MED + V 4  9.6b 7  4.7b 6  7.7b
Left ventricular workload
(kgm/min)
71  23 MED 21  2b 24  7b 23  2b
MED + V 42  13a,b 38  10a,b 31  11b
Stroke volume index
(mL/beat/kg)
2.1  0.5 MED 1.4  0.2b 1.5  0.3b 1.6  0.3b
MED + V 2.4  0.6 2.1  0.3 1.8  0.8
Systemic vascular resistance index
(mmHg/mL/min/kg)
1.4  0.4 MED 2.2  0.3b 1.8  0.3 1.8  0.4
MED + V 1.3  0.6 1.3  0.4 1.6  0.9
Pulmonary vascular resistance index
(mmHg/mL/min/kg)
0.2  0.1 MED 0.2  0.1 0.2  0.1 0.2  0.1
MED + V 0.1  0.1 0.1  0.1 0.1  0.04
Arterial oxygen content
(mL/dL)
19  1.6 MED 19  1.6 19  2.2 19  1.8
MED + V 21  1.7 22  2.0a,b 21  2.8b
Mixed venous oxygen content
(mL/dL)
15  1.7 MED 13  1.7 14  2.5 13  2.6
MED + V 17  1.7a 18  2.9a,b 17  3.6a
Arterial O2 tension (mmHg) 106  2.7 MED 287  100b 278  93b 250  112b
MED + V 284  109b 283  142b 260  118b
Mixed venous O2 tension (mmHg) 39  3.0 MED 33  3.1 35  4.1 35  6.4
MED + V 42  1.7a 47  8.2a,b 46  10a,b
Mixed venous blood O2 saturation (%) 79  0.0 MED 71  0.1 74  0.1 73  0.1
MED + V 83  0.0a 85  0.1a 84  0.1a
Arterial CO2 tension
(mmHg)
40  2.1 MED 43  3.3 45  4.7 47  5.3
MED + V 46  3.7 49  4.3 50  5.5
Oxygen delivery index
(mL/min/kg)
15.1  4.3 MED 7.4  1.2b 9.1  2.7b 8.3  1.4b
MED + V 15.3  4.8a 15.4  4.1a 13.2  7.0
Oxygen consumption index
(mL/min/kg)
3.2  0.7 MED 2.4  0.1b 2.5  0.3b 2.2  0.2b
MED + V 3.0  0.9 2.4  0.3b 2.1  0.6b
Oxygen extraction ratio
(%)
20  3 MED 33  5b 29  6b 28  6b
MED + V 20  2a 17  6a 19  8a
Venous admixture
(%)
– MED 14  4.5 17  4.8 18  6.5
MED + V 19  6.9 22  9.8 20  10.9
Alveolar dead space ventilation
(%)
– MED 0.16  0.03 0.16  0.06 0.17  0.05
MED + V 0.17  0.05 0.17  0.03 0.20  0.02
a Signiﬁcant differences (P < 0.05) between treatments (change from baseline was compared between the treatments for all parameters other than mixed venous blood O2
saturation, venous admixture and alveolar dead space ventilation which were compared by time points).
b Within treatment differences (P < 0.05) compared to baseline at a given time point.
4 H.A. Tapio et al. / The Veterinary Journal 251 (2019) 105345dobutamine. Dobutamine increases MAP by increasing myocardial
contractility, and thus, _Qt, although with low doses (0.5 mg/kg/
min) increases in _Qt have not been consistently detected in horses
(Raisis et al., 2000; Loughran et al., 2017). Our observations ofhigher LVW and SVI with MED + V compared to MED likely reﬂect
increased myocardial contractility, an effect of dobutamine.
A medetomidine CRI decreases CI and increases SVR in
anesthetized horses (Ringer et al., 2007; Risberg et al., 2016),
H.A. Tapio et al. / The Veterinary Journal 251 (2019) 105345 5which was observed in the present study, whereas with MED + V,
SVRI and CI remained mainly at baseline levels. Vatinoxan is
known to alleviate the peripheral cardiovascular effects of α2-
agonists, mainly by antagonizing vasoconstriction, and conse-
quently, a normal SVR is maintained and a reﬂex bradycardia is
prevented (Bryant et al., 1998; Pagel et al., 1998). In the present
study, the more stable SVRI and CI likely contributed to improved
DO2I and O2ER% with MED + V compared to MED, suggesting
improved tissue oxygen delivery with MED + V. The increase in
O2ER% likely reﬂects the increasing oxygen cleavage from blood by
tissues in face of decreasing DO2I. However, to conﬁrm whether
oxygen delivery is improved in speciﬁc tissues with vatinoxan,
perfusion and local blood ﬂow should be measured directly (Raisis
et al., 2000; Wittenberg-Voges et al., 2018). It is noteworthy that
our results (signiﬁcant decreases in CI and DO2I and increases in
O2ER% with MED) indicate that medetomidine CRI during general
anesthesia can compromise tissue oxygen delivery and local
perfusion, even though commonly observed cardiovascular
parameters (i.e. MAP and HR) may remain clinically acceptable.
This should be considered especially when anesthetizing horses
with cardiovascular compromise.
Certain drugs, particularly α2-agonists and ketamine, have been
shown to interact with LiDCO lithium sensors in vitro, potentially
causing bias in _Qt measurements (Ambrisko et al., 2013). However,
the plasma concentrations of these drugs measured in the present
study were lower than those causing signiﬁcant alterations in
sensor voltage in vitro, and therefore, signiﬁcant biases in _Qt
measurements, and parameters calculated thereof, would be
unlikely.
Hemoglobin and CaO2 concentration increased signiﬁcantly
with MED + V at the same time point (T40). Concurrent increases
in Hb and CaO2 have been reported before with dobutamine in
anesthetized horses and attributed to splenic contraction, thus
increasing Hb concentrations and the oxygen-carrying capacity of
blood (Loughran et al., 2017). The increases in mixed venous
blood oxygenation parameters with MED + V may partly be
related to increased Hb concentrations or, furthermore, to
improved hemodynamics, as previously reported in horses
receiving vatinoxan and other α2-agonists (Pakkanen et al.,
2015; de Vries et al., 2016; Tapio et al., 2018). Based on the PaO2
results, oxygenation of blood, however, was adequate with both
treatments.
Fecal output decreased after general anesthesia in all horses,
but no horses showed signs of gastrointestinal distress. Vatinoxan
did not inﬂuence the decrease, despite reports of it improving
gastrointestinal borborygmi in standing horses sedated with
detomidine (Vainionpää et al., 2013; Tapio et al., 2018) or
romiﬁdine (de Vries et al., 2016). It is possible that the
gastrointestinal suppression associated with general anesthesia
lasted longer than the effects of a single dose of vatinoxan
administered before the anesthesia.
No difference was detected between the treatments in sedation
scores after premedication, nor in plasma drug concentrations of
medetomidine, in contrast to previous reports with other α2-
agonists (Vainionpää et al., 2013; Pakkanen et al., 2015; de Vries
et al., 2016). The small number of sampling time points for the
determination of plasma drug concentrations did not allow for
further pharmacokinetic analysis. However, enhanced circulation
with MED + V may have resulted in faster induction because the
distribution of midazolam and ketamine to the brain was
facilitated.
This study design reﬂects clinical practice, as balancing
inhalation anesthesia with a medetomidine CRI has become
popular in horses (Gozalo-Marcilla et al., 2017). It does not,
however, allow comparisons with isoﬂurane anesthesia without
any adjunctive CRI. Recently, further concerns about the effect ofmedetomidine CRI on cardiovascular function in horses have been
reported (Risberg et al., 2016). Whether the protocols investigated
in our study have advantages over sole isoﬂurane anesthesia with
regard to cardiovascular function remains to be determined.
Conclusions
Combining vatinoxan with medetomidine for premedication
resulted in hypotension that responded to dobutamine infusion,
and cardiac performance and oxygen delivery were maintained.
However, further research is warranted to limit the hypotensive
effect of vatinoxan in anesthetized horses. Although heart rate and
arterial blood pressures remained clinically acceptable with MED,
cardiac performance and tissue oxygen delivery were lower than
with MED + V.
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